^
    Back
    Association details:
    Biomarker:HER-2 mutation
    Cancer:Lung Cancer
    Drug:Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Afatinib in NSCLC With HER2 Mutation

    Excerpt:
    ...- Tumour block available for central review of HER2 mutation status....
    Trial ID:
    NICHE
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Afatinib in NSCLC With HER2 Mutation

    Excerpt:
    ...- Tumor tissue with HER2 mutations as confirmed by AmoyDx® HER2 Mutation Detection Kit...
    Trial ID:
    NCT02597946
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non Small Cell Lung Cancer

    Excerpt:
    ...Evaluation of the HER-2 gene copy number and amplification`DNA Extraction and Mutational Analysis of EGFR and HER-2`Toxicity evaluation`Determination of plasma HGF pre and post-treatment concentration...
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancers (Basel)
    Title:

    Real-World Treatment Outcomes and Safety of Afatinib in Advanced Squamous Cell Lung Cancer Progressed after Platinum-Based Doublet Chemotherapy and Immunotherapy (SPACE Study)

    Published date:
    11/24/2023
    Excerpt:
    This study aimed to evaluate treatment outcomes and safety of afatinib in patients with squamous cell carcinoma of the lung (LSCC) who progressed after chemotherapy and immunotherapy....The TTF in patients with ERBB2 mutations was significantly longer than that in patients without (6.8 vs. 2.1 months, p = 0.045).
    DOI:
    https://doi.org/10.3390/cancers15235568